Page 6 - National Suicide Lifeline News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from National suicide lifeline. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In National Suicide Lifeline Today - Breaking & Trending Today

ABC Health - WOND

FatCamera/Getty Images(NEW YORK) A new medication just approved by the U.S. Food and Drug Administration could revolutionize the treatment of postpartum depression, a condition that affects as many as 1 in 8 women who have recently given birth.

The medication, zuranolone, to be sold under the brand name Zurzuvae, is the first oral pill to ever be approved by the FDA to treat postpartum depression, a depression that occurs after having a baby.

"Postpartum depression is a serious and potentially life-threatening condition in which women experience sadness, guilt, worthlessness even, in severe cases, thoughts of harming themselves or their child. And, because postpartum depression can disrupt the maternal-infant bond, it can also have consequences for the child s physical and emotional development," Dr. Tiffany R. Farchione, director of the Division of Psychiatry at the FDA s Center for Drug Evaluation and Research, said in a statement. "Having access to a ....

United States , Darien Sutton , Tiffanyr Farchione , Journal Of The American Medical Association Psychiatry , Us Centers For Disease , Drug Enforcement Administration , Division Of Psychiatry , National Suicide Lifeline , Drug Administration , Drug Evaluation , Disease Control , Sage Therapeutics , American Journal , American Medical Association , Good Morning , Ond Am , Ews Talk , Atlantic City , New Jersey , South Jersey , Adio You Can Depend On , Ackie Parks ,

Five things to know about first-ever FDA-approved pill for postpartum depression

Five things to know about first-ever FDA-approved pill for postpartum depression
theranch.fm - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theranch.fm Daily Mail and Mail on Sunday newspapers.

United States , Darien Sutton , Tiffanyr Farchione , Drug Administration , National Suicide Lifeline , Us Centers For Disease , Division Of Psychiatry , Drug Enforcement Administration , Journal Of The American Medical Association Psychiatry , Drug Evaluation , Disease Control , Sage Therapeutics , American Journal , American Medical Association , Good Morning ,

Health - 1540 WADK Newport

FatCamera/Getty Images(NEW YORK) A new medication just approved by the U.S. Food and Drug Administration could revolutionize the treatment of postpartum depression, a condition that affects as many as 1 in 8 women who have recently given birth.

The medication, zuranolone, to be sold under the brand name Zurzuvae, is the first oral pill to ever be approved by the FDA to treat postpartum depression, a depression that occurs after having a baby.

"Postpartum depression is a serious and potentially life-threatening condition in which women experience sadness, guilt, worthlessness even, in severe cases, thoughts of harming themselves or their child. And, because postpartum depression can disrupt the maternal-infant bond, it can also have consequences for the child s physical and emotional development," Dr. Tiffany R. Farchione, director of the Division of Psychiatry at the FDA s Center for Drug Evaluation and Research, said in a statement. "Having access to a ....

United States , Darien Sutton , Tiffanyr Farchione , Division Of Psychiatry , National Suicide Lifeline , Drug Administration , Drug Enforcement Administration , Journal Of The American Medical Association Psychiatry , Us Centers For Disease , Drug Evaluation , Disease Control , Sage Therapeutics , American Journal , American Medical Association , Good Morning , Radio Station , Ews Talk , Rhode Island , Adk Am , 540 Am , 01 1 Fm , 01 1 , Igh School Sports , Alk Of The Town , Potlight On Giving , Ig Ticket ,

Health - KSYL-AM

FatCamera/Getty Images(NEW YORK) A new medication just approved by the U.S. Food and Drug Administration could revolutionize the treatment of postpartum depression, a condition that affects as many as 1 in 8 women who have recently given birth.

The medication, zuranolone, to be sold under the brand name Zurzuvae, is the first oral pill to ever be approved by the FDA to treat postpartum depression, a depression that occurs after having a baby.

"Postpartum depression is a serious and potentially life-threatening condition in which women experience sadness, guilt, worthlessness even, in severe cases, thoughts of harming themselves or their child. And, because postpartum depression can disrupt the maternal-infant bond, it can also have consequences for the child s physical and emotional development," Dr. Tiffany R. Farchione, director of the Division of Psychiatry at the FDA s Center for Drug Evaluation and Research, said in a statement. "Having access to a ....

United States , Darien Sutton , Tiffanyr Farchione , Drug Administration , Drug Enforcement Administration , Us Centers For Disease , National Suicide Lifeline , Division Of Psychiatry , Journal Of The American Medical Association Psychiatry , Drug Evaluation , Disease Control , Sage Therapeutics , American Journal , American Medical Association , Good Morning , Syl 970 , Syl 104 9 , Ush Linbaugh , Sean Hannity , Ave Graichen , Oast To Coast , Mark Levin , Ichael Savage , Bs Radio News , Oon Griffon , Im Komando ,

Health - Carroll Broadcasting Inc.

FatCamera/Getty Images(NEW YORK) A new medication just approved by the U.S. Food and Drug Administration could revolutionize the treatment of postpartum depression, a condition that affects as many as 1 in 8 women who have recently given birth.

The medication, zuranolone, to be sold under the brand name Zurzuvae, is the first oral pill to ever be approved by the FDA to treat postpartum depression, a depression that occurs after having a baby.

"Postpartum depression is a serious and potentially life-threatening condition in which women experience sadness, guilt, worthlessness even, in severe cases, thoughts of harming themselves or their child. And, because postpartum depression can disrupt the maternal-infant bond, it can also have consequences for the child s physical and emotional development," Dr. Tiffany R. Farchione, director of the Division of Psychiatry at the FDA s Center for Drug Evaluation and Research, said in a statement. "Having access to a ....

United States , Tiffanyr Farchione , Darien Sutton , Drug Administration , Division Of Psychiatry , Drug Enforcement Administration , National Suicide Lifeline , Journal Of The American Medical Association Psychiatry , Us Centers For Disease , Drug Evaluation , Disease Control , Sage Therapeutics , American Journal , American Medical Association , Good Morning , Awas , 04 7 , West Branch , P North , Awas Bay ,